Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| ST STSASatsuma Pharmaceuticals | $1.10+0.0% | — | 1 assetsStage unavailable | No dated catalyst | |
| ST STTKShattuck Labs Inc | $7.53+3.9% | $755.7M | 8 assetsStage unavailable | No dated catalyst | |
| SU SUPNSupernus Pharmaceuticals | $45.85-3.4% | $2.67B |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
17 assetsStage unavailable |
| No dated catalyst |
| SU SURFSurface Oncology Inc | $1.07+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| SV SVASinovac Biotech | $6.47+0.0% | $642.4M | 5 assetsStage unavailable | No dated catalyst |
| SV SVRASavara | $5.59+1.8% | $1.15B | 1 assetsPDUFA | MOLBREEVI (Molgramostim)PDUFA · Approval decision |
| SW SWTXSpringWorks Therapeutics Inc | $46.99+0.0% | $3.54B | 14 assetsStage unavailable | No dated catalyst |
| SX SXTP60 Degree Pharmaceuticals | $1.13+0.0% | $4.0M | 5 assetsPhase 2 | Arakoda (Tafenoquine)Phase 2 · Data readout |
| SY SYBXSynlogic Inc | $1.20-1.6% | $14.7M | 4 assetsStage unavailable | No dated catalyst |
| SY SYGGFSynairgen | $0.00+0.0% | $110,266 | 2 assetsStage unavailable | No dated catalyst |
| SY SYRESpyre Therapeutics Inc | $106.49-1.2% | $9.39B | 6 assetsPhase 2 | SPY003Phase 2 · Data readout |
| SY SYRSSyros Pharmaceuticals | $0.00-75.0% | $2,683 | 9 assetsStage unavailable | No dated catalyst |
| TA TAKTakeda | $18.18+0.3% | $58.06B | 5 assetsApproved | Rusfertide (Hepcidin Mimetic)PDUFA · Approval decision |
| TA TALSTalaris Therapeutics | $47.98+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| TA TARAProtara Therapeutics | $3.85-1.3% | $227.5M | 3 assetsPhase 3 | IV Choline chloridePhase 3 · Data readout |
| TA TARSTarsus Pharmaceuticals | $72.70+1.7% | $3.19B | 6 assetsPhase 2 | TP-05Phase 2 · Data readout |
| TB TBPHTheravance Biopharma | $17.01+0.4% | $883.1M | 7 assetsStage unavailable | No dated catalyst |
| TC TCRTAlaunos Therapeutics | $1.76-1.1% | $4.5M | 2 assetsStage unavailable | No dated catalyst |
| TC TCRXTScan Therapeutics | $0.78+0.4% | $52.8M | 3 assetsPhase 1 | TSC-101Phase 1 · Data readout |
| TE TECXTectonic Therapeutic | $37.63+4.4% | $735.6M | 4 assetsPhase 2 | TX2100Phase 1a · Data readout |
| TE TELOTelomir Pharmaceuticals | $1.13+0.9% | $77.7M | 1 assetsStage unavailable | No dated catalyst |
| TE TENXTenax Therapeutics | $1.75-1.7% | $65.5M | 1 assetsStage unavailable | No dated catalyst |
| TE TERNTerns Pharmaceuticals | $52.95+0.0% | $6.12B | 5 assetsStage unavailable | No dated catalyst |
| TE TEVATeva Pharmaceutical Industries Ltd | $37.34+1.4% | $43.51B | 16 assetsPDUFA | TEV-’248 (ICS/SABA)Phase 3 · Data readout |
| TG TGTXTG Therapeutics | $54.27+7.3% | $8.31B | 9 assetsPhase 3 | Azercabtagene zapreleucel (azer-cel)Phase 1 · Data readout |
| TH THARTharimmune | $2.19-0.9% | $187.4M | 1 assetsStage unavailable | No dated catalyst |
| TH THRXTheseus Pharmaceuticals | $4.06+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| TH THTXTheratechnologies Inc | $3.39+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| TI TILInstil Bio | $7.58+2.0% | $51.4M | 4 assetsStage unavailable | No dated catalyst |
| TL TLPHTalphera, Inc | $1.19+0.0% | $61.8M | 3 assetsStage unavailable | No dated catalyst |
| TL TLSATiziana Life Sciences | $1.14+1.8% | $145.1M | 7 assetsPhase 2 | Intranasal Foralumab (anti-CD3 mAb)Phase 2a · Data readout |
| TM TMDXTransMedics Group | $94.77+4.3% | $3.29B | 5 assetsStage unavailable | No dated catalyst |
| TN TNGXTango Therapeutics | $23.88+1.6% | $4.03B | 5 assetsPhase 1/2 | TNG456Phase 1/2 · Data readout |
| TN TNXPTonix Pharmaceuticals | $12.55+1.3% | $215.2M | 21 assetsPhase 2 | TNX-102 SL Phase 2 · Data readout |
| TN TNYATenaya Therapeutics | $0.70+1.0% | $156.4M | 3 assetsPhase 1/2 | TN-201Phase 1/2 · Data readout |
| TO TOVXTheriva Biologics | $0.24+2.1% | $10.8M | 3 assetsPhase 2 | VCN-01 (zabilugene almadenorepvec) (Oncolytic Adenovirus)Phase 2 · Data readout |
| TR TRAWTraws Pharma, Inc. | $0.53+1.9% | $8.1M | 7 assetsStage unavailable | No dated catalyst |
| TR TRMLTourmaline Bio | $47.98+0.0% | $1.23B | 3 assetsStage unavailable | No dated catalyst |
| TR TRVITrevi Therapeutics | $17.96-1.6% | $2.56B | 3 assetsStage unavailable | No dated catalyst |
| TR TRVNTrevena Inc | $0.01+0.0% | $9,501 | 5 assetsStage unavailable | No dated catalyst |